2003; baxter - Supplements - Haematologica

IV International Workshop on Immune Tolerance in Hemophilia63Genet 1995;10:119-21.9. Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL,et al. Further characterization of factor VIII-deficientmice created by gene targeting: RNA and protein studies.Blood 1996;88:3446-50.10. Muchitsch EM, Turecek PL, Zimmermann K, Pichler L,Auer W, Richter G, et al. Phenotypic expression ofmurine hemophilia. Thromb Haemost 1999;82:1371-3.11. Connelly S, Andrews JL, Gallo AM, Kayda DB, Qian J,Hoyer L, et al. Sustained phenotypic correction ofmurine hemophilia A by in vivo gene therapy. Blood1998;91:3273-81.12. Qian J, Borovok M, Bi L, Kazazian Jr HH, Hoyer LW.Inhibitor development and T cell response to humanfactor VIII in murine haemophilia A. Thromb Haemost1999;81:240-4.13. Balague C, Zhou J, Dai Y, Alemany R, Josephs SF,Andreason G, et al. Sustained high-level expression offull-length human factor VIII and restoration of clottingactivity in hemophilic mice using a minimal adenovirusvector. Blood 2000;95:820-8.14. Elder B, Lakich D, Gitschier J. Sequence of the murinefactor VIII cDNA. Genomics 1993;16:374-9.15. Reipert BM, Ahmad RU, Turecek PL, Schwarz HP. Characterizationof antibodies induced by human factor VIIIin a murine knockout model of hemophilia A. ThrombHaemost 2000;84:826-32.16. Sasgary M, Ahmad RU, Schwarz HP, Turecek PL, ReipertBM. Single cell analysis of factor VIII-specific T-cells inhemophilic mice after treatment with human factorVIII. Thromb Haemost 2002;87:266-72.17. Hausl C, Maier E, Schwarz HP, Ahmad RU, Turecek PL,Dorner F, Reipert BM. Long-term persistence of antifactorVIII antibody-secreting cells in hemophilic miceafter treatment with human factor VIII. ThrombHaemost 2002;87:840-5.18. Slifka MK, Antia R, Withmire JK, Ahmed R. Humoralimmunity due to long-lived plasma cells. Immunity1998; 8:363-72.19. Manz RA, Löhning M, Cassese G, Thiel A, Radbruch A.Survival of long-lived plasma cells is independent ofantigen. Intern Immunol 1998;11:1703-11.20. Ochsenbein AF, Pinschewer DD, Sierro S, Horvath E,Hengartner H, Zinkernagel RM. Protective long-termantibody memory by antigen-driven T help-dependentdifferentiation of long-lived memory B-cells to shortlivedplasma cells independent of secondary lymphoidorgans. Proc Am Acad Sci USA 2000;97:13263-8.21. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ.Immune regulation by CD40 and its ligand GP39. AnnRev Immunol 1996;14:591-617.22. Larsen CP, Alexander DZ, Hollenbaugh D, Elwood ET,Ritchie SC, Aruffo A, et al. CD40-gp39 interactions playa critical role during allograft rejection: suppression ofallograft rejection by blockade of the CD40-gp39 pathway.Transplantation 1996;61:4-9.23. Kirk AD, Burkly LC, Batty DC, Baumgartner RE, BerningJD, Buchanan K. Treatment with humanized monoclonalantibody against CD154 prevents acute renalallograft rejection in nonhuman primates. Nat Med1999;5:686-93.24. Durie FH, Aruffo A, Ledbetter J, Crassi KM, Green WR,Fast LD, et al. Antibody to the ligand of CD40, gp39,blocks the occurrence of the acute and chronic forms ofgraft-vs-host-disease. J Clin Invest 1994;94:1333-8.25. Saito K, Sakurai J, Ohata J, Kohsaka T, Hashimoto H,Okumura K, et al. Involvement of CD40 ligand-CD40and CTLA4-B7 pathways in murine acute graft-versushostdisease induced by allogeneic T cells lacking CD28.J Immunol 1998;160:4225-31.26. Gerritse K, Laman JD, Noeller RJ, Aruffo A, Ledbetter JA,Boersma WJA, et al. CD40-CD40 ligand interactions inexperimental allergic encephalomyelitis and multiplesclerosis. Proc Natl Acad Sci USA 1996;93:2499-504.27. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibodytreatment prevents the development of lupus-likenephritis in a subset of New Zealand black x NewZealand white mice. Response correlates with theabsence of an anti-antibody response. J Immunol 1996;157:3159-64.28. Taylor PA, Friedman TM, Korngold R, Noelle RJ, BlazarBR. Tolerance induction of alloreactive T cells via ex vivoblockade of the CD40:CD40L costimulatory pathwayresults in the generation of a potent immune regulatorycell. Blood 2002;99:4601-929. Reipert BM, Sasgary M, Ahmad RU, Auer W, TurecekPL, Schwarz HP. Blockade of CD40/CD40 ligand interactionsprevents induction of factor VIII inhibitors inhemophilic mice but does not induce lasting immunetolerance. Thromb Haemost 2001;86:1345-52.30. Qian J, Burkly LC, Smith EP, Ferrant JL, Hoyer LW, ScottDW, et al. Role of CD154 in the secondary immuneresponse: the reduction of pre-existing splenic germinalcenters and anti-factor VIII inhibitor titers. Eur JImmunol 2000;30:2548-54.31. Rossi G, Sarakar J, Scandella D. Long-term induction ofimmune tolerance after blockade of CD40-CD40Linteraction in a mouse model of hemophilia A. Blood2001;97:2750-6.32. Qian J, Collins M, Sharpe AH, Hoyer LW. Preventionand treatment of factor VIII inhibitors in murine hemophiliaA. Blood 2000;95:1324-9.33. Sarkar R, Gao GP, Chirmule N, Tazelaar J, Kazazian HH.Partial correction of the murine hemophilia A with neoantigenicmurine factor VIII. Hum Gene Ther 2000;11:881-94.34. Dazzi F, Rosato A, Tison T, Vianello F, Radossi P, GirolamiA. An animal model to explore the molecular basisof factor VIII (FVIII) inhibitor formation: evidence ofanti-FVIII T-cell response and importance of administrationroute (abstract). Thromb Haemost 1995; 73:1026.35. Jarvis MA, Levin LG, Harrison JA, De Pianto DJ, SuzukiCM, Ziaja CL, et al. Induction of human factor VIIIinhibitors in rats by immunization with human recombinantfactor VIII: a small animal model for humanswith high responder inhibitor phenotype. ThrombHaemost 1996;75:318-25.36. Levin LG, Jarvis M, Powell J, Harrison JA, Reisner HM.Induction of human factor VIII inhibitors in rats 2: finemapping of rat anti-human rFVIII antibodies. ThrombHaemost 1996;76:998-100337. Chao H, Walsh CE. Induction of tolerance to humanfactor VIII in mice. Blood 2001;97:3311-238. Bosma GC, Carroll AM. The SCID mouse mutant: definition,characterization and potential uses. Annu RevImmunol 1991;9:323-50.39. Araki R, Fujimori A, Hamatani K, Mita K, Saito T, MoriM, et al. Nonsense mutation at Tyr-4046 in the DNAdependentprotein kinase catalytic subunit of severecombined immune deficiency mice. Proc Natl Acad SciUSA 1997;94:2438-83.40. Laulan A, Sauger A, Germain C, Montembault AM, SansI, Potentini-Esnault C, et al. Frequency of anti-FVIIIantibodies in humanized SCID mice elicited by recombinantdeleted factor VIII and by plasma derived factorVIII. J Immunol Methods 1997;210:205-14.41. Vanzieleghem B, Gilles JG, Desqueper B, Vermylen J,Saint-Remy JM. Humanized Severe Combined ImmunodeficientMice as a Potential Model for the Study ofTolerance to Factor VIII. Thromb Haemost 2000; 83:833-9.42. Gilles JG, Vanzieleghem B, Saint-Remy JM. Animalmodels to explore mechanisms of tolerance induction toFVIII: SCID mice and SCID-FVIII-KO mice. Haematologica2000; 85 Suppl:103-7.haematologica vol. 88(supplement n. 12):september 2003